Immunome, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 9, 2026, reporting a net loss of $212.749 million for the nine months ended September 30, 2026.

Key Highlights

  • Nine-month net loss: The company reported a net loss of $212.749 million for the nine months ended September 30, 2026, compared to $142.494 million for the same period in 2025.
  • Third-quarter net loss: Net loss for the three months ended September 30, 2026 was $85.783 million, versus $57.457 million in Q3 2025.
  • Total assets: Total assets stood at $505.527 million as of September 30, 2026, down from $683.188 million as of December 31, 2025.
  • Cash and marketable securities: Cash and cash equivalents were $212.842 million and marketable securities were $248.740 million as of September 30, 2026; cash was $653.482 million and marketable securities were zero as of December 31, 2025.
  • Accumulated deficit: The accumulated deficit reached $940.913 million as of September 30, 2026, up from $728.164 million at December 31, 2025.
  • Shares outstanding: There were 118,072,943 shares of common stock outstanding as of November 4, 2026.
  • No collaboration revenue: The company reported zero collaboration revenue for both the three and nine months ended September 30, 2026, compared to $6.941 million for the nine months ended September 30, 2025.

Immunome's Financial Position and Operating Results for the Nine Months Ended September 30, 2026

According to the filing, Immunome, Inc. (NASDAQ:IMNM) reported total operating expenses of $227.828 million for the nine months ended September 30, 2026, compared to $158.193 million for the same period in 2025. Research and development expenses accounted for $175.772 million of that total, up from $126.516 million in the prior-year period. General and administrative expenses were $52.056 million for the nine months ended September 30, 2026, compared to $31.677 million for the nine months ended September 30, 2025.

For the third quarter alone, the company reported total operating expenses of $90.362 million, with research and development at $69.506 million and general and administrative at $20.856 million, the filing disclosed. Interest income of $4.579 million partially offset the operating loss in Q3 2026, while interest income for the nine-month period was $15.079 million. The net loss per share, basic and diluted, was $(0.76) for Q3 2026 and $(1.88) for the nine months ended September 30, 2026, based on weighted-average shares outstanding of 113,564,748 and 113,326,406, respectively.

The company's balance sheet as of September 30, 2026 reflected total stockholders' equity of $454.303 million, compared to $634.343 million at December 31, 2025, according to the filing. Share-based compensation expense for the nine months ended September 30, 2026 totaled $29.513 million, as reported in the cash flow statement. The company's common stock had 300,000,000 shares authorized at September 30, 2026, with 113,647,456 shares issued and outstanding at that date. No shares of preferred stock were issued or outstanding at either balance sheet date, the filing stated.

What Was Disclosed

Immunome filed its quarterly report for the period ended September 30, 2026, disclosing a nine-month net loss of $212.749 million, zero collaboration revenue, total assets of $505.527 million, and an accumulated deficit of $940.913 million, with 118,072,943 shares outstanding as of November 4, 2026.